KetoAir™ Breathalyzer
Ketosis Monitoring / Metabolic Health
CommercialFDA Class I Registered; Exploring Commercialization
Key Facts
Indication
Ketosis Monitoring / Metabolic Health
Phase
Commercial
Status
FDA Class I Registered; Exploring Commercialization
Company
About Avalon GloboCare
Founded in 2016 and uplisted to Nasdaq in 2018, Avalon GloboCare is advancing precision diagnostics through its proprietary platforms. The company's KetoAir™ breathalyzer is an FDA-registered Class I medical device for ketosis monitoring, while its QTY code platform, developed with MIT, is focused on designing water-soluble cytokine receptors. Avalon operates with approximately 60 full-time employees and is actively expanding its intellectual property portfolio and strategic partnerships.
View full company profile